Here’s What to Expect From CME Group’s Next Earnings Report

CME Group Inc. (CME), headquartered in Chicago, Illinois, operates contract markets for the trading of futures and options on futures contracts. Valued at $95.6 billion by market cap, the company offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, and more. It facilitates trading on its trading floors, electronic platform, and through privately negotiated transactions that it clears. The leading derivatives marketplace is expected to announce its fiscal fourth-quarter earnings for 2025 before the market opens on Wednesday, Feb. 4.

Ahead of the event, analysts expect CME to report a profit of $2.72 per share on a diluted basis, up 7.9% from $2.52 per share in the year-ago quarter. The company has consistently surpassed Wall Street’s EPS estimates in its last four quarterly reports.

• Ignore the Apple Noise and Consider Buying Qualcomm Stock for 2026

• If You Missed the Boat, Nvidia (NVDA) Stock Options Are Giving You Another Ticket

• Alphabet Stock Is Still Undervalued According to Analysts – 1 Month GOOGL Puts Yield 2.50%

• Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won’t find anywhere else.

For the full year, analysts expect CME to report EPS of $11.17, up 8.9% from $10.26 in fiscal 2024. Its EPS is expected to rise 4% year over year to $11.62 in fiscal 2026.

CME stock has underperformed the S&P 500 Index’s ($SPX) 19.3% gains over the past 52 weeks, with shares up 17% during this period. However, it outperformed the Financial Select Sector SPDR Fund’s (XLF) 13.8% gains over the same time frame.

On Oct. 22, 2025, CME shares closed down marginally after reporting its Q3 results. Its adjusted EPS of $2.68 topped Wall Street expectations of $2.63. The company’s revenue was $1.54 billion, topping Wall Street forecasts of $1.53 billion.

Analysts’ consensus opinion on CME stock is moderately bullish, with a “Moderate Buy” rating overall. Out of 17 analysts covering the stock, five advise a “Strong Buy” rating, two suggest a “Moderate Buy,” seven give a “Hold,” one recommends a “Moderate Sell,” and two advocate a “Strong Sell.” CME’s average analyst price target is $292.33, indicating a potential upside of 8.9% from the current levels.

On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com